Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

Urothelial carcinoma trial updates from ASCO 2018

Bradley McGregor, MD, of the Dana-Farber Cancer Institute, Boston, MA, discusses exciting urothelial carcinoma therapy updates from the American Society of Oncology (ASCO) 2018 Annual Meeting, held in Chicago, IL. Dr McGregor covers results and updates from: the comparison of nab-paclitaxel and paclitaxel in the advanced setting (NCT02033993); the Phase I EV-101 study of enfortumab vedotin (NCT02091999) in platinum-refractory patients; the Phase II EV-201 study (NCT03219333) in platinum-refractory and naive patients; and the Phase II study of erdafitinib (NCT02365597) in patients with metastatic or unresectable disease with FGFR alterations. He also highlights the importance of continuing research to prevent disease progression, mentioning two studies investigating atezolizumab (ABACUS; NCT02662309) and pembrolizumab (PURE-01; NCT02736266) in the neoadjuvant setting.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.